Navigation Links
Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
Date:9/23/2013

0-542-0970; or JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, or via telephone at 415-835-8985; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or via telephone at 800-747-3924. 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Sangamo, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Proposes Public Offering Of Common Stock
2. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
3. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
4. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
6. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
9. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
10. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
(Date:3/29/2015)... 2015 As a symbol of its ... our pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to ... Berkenstock Race Team for the 2015 race season. Success ... but a strong sense of precision and attention to ... success in the quality control testing laboratory. Sponsorship of ...
(Date:3/27/2015)... March 27, 2015 The consumption of ... of the recession and high prices in 2008. However, ... recovered and keeps on gaining momentum now. , To ... at more than 100,000 thousand tonnes. No considerable growth ... the global capacity rocketed during 2012-2013, registering 11% growth ...
(Date:3/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... prearranged trading plan in accordance with Securities and Exchange ... CEO of Neogen Corporation, is a minority owner of ... stock. Herbert does not have control of ... filing is only for a portion of the shares ...
Breaking Biology Technology:Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Neogen CEO adopts 10b5-1 Trading Plan 2
... ... Cardiovascular Drug, CALGARY, June ... to developing a portfolio of,therapeutic proteins for metabolic and cardiovascular ... (safflower Apo AI(Milano)) is functional in a widely accepted,animal model. ...
... 5 Anesiva,Inc. (Nasdaq: ANSV ) today ... its NF-kappa B Decoy (NF-kB Decoy) program, which ... Therapeutics,Inc. (TFT). NF-kB Transcription Factor Decoy inhibits NF-kappa ... diseases such as inflammatory,bowel disease (IBD), eczema, rheumatoid ...
... Shuji Nakamura, Director UC Santa Barbara,s Solid-State Lighting and ... 2008 Prince of Asturias Award for Technical and Scientific ... with a medal and a Joan Miro sculpture commissioned ... also share a 50,000 (US$77,000) stipend. , The Technical ...
Cached Biology Technology:SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano) 2SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano) 3SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano) 4Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 2Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 3
(Date:3/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... starting March 30 th . The ... New York markets. Gino ... our new ad campaign following the recent initial shipment of ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts ...
(Date:3/17/2015)... , March 17, 2015 Emotient, the ... software, today announced general availability of Emotient ... for the analysis of facial expressions. The system ... media content, products and services. It delivers audience ... and sentiment - as derived from facial evidence ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... blockers were first used clinically, scientists can finally get ... beta2-adrenergic receptor. This receptor hails from a family of ... bodily functions, several of our senses, and the action ... the first known structure of a human GPCR, the ...
... study concludes that increasing levels of ozone due to ... vegetation, resulting in serious costs to the world,s economy. ... of Energy Policy, focused on how three environmental changes ... human activity will affect crops, pastures, and forests. ...
... South East Asia with the official launch of SCI ... 27th November 2007. Followed by detailed research ... markets worldwide, with overwhelming support and enthusiasm towards SCIs ... SCI India will offer its membership the opportunity to ...
Cached Biology News:Scientists unveil structure of molecular target of many drugs 2MIT: Human-generated ozone will damage crops 2MIT: Human-generated ozone will damage crops 3SCI marks expansion into Asia with the launch of SCI INDIA 2
... Compound(s) tested through 63 ... assays spanning a broad ... panel includes many non ... several non-selective assays. ...
...
... The Genome Sequencer 20 System revolutionizes ... massively parallel fashion. The Genome Sequencer ... accessories Reagents and consumables for library ... for mapping and de novo assembly ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: